Back HIV Prevention

Coverage of 2015 Interscience Conference on Antimicrobial Agents and Chemotherapy

HIVandHepatitis.com coverage of the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, September 17-21, 2015.

Highlights of this year's conference include experimental antiretroviral drugs and treatment strategies, HIV prevention, and comorbidities among people with HIV and HIV/HCV coinfection.

Full listing by topic

ICAAC website

10/6/15

alt

Coverage of IDWeek 2015

HIVandHepatitis.com coverage of IDWeek 2015, October 7-11 in San Diego.

Conference highlights include new HIV therapies and treatment strategies, HIV and hepatitis C continuums of care, and comorbidities among people with HIV and HIV/HCV coinfection, as well as news about antibiotic stewardship and other infectious diseases including Ebola virus.

Full listing of coverage by topic

IDWeek website

10/9/15

alt

 

September 18 is National HIV/AIDS and Aging Awareness Day

Friday, September 18, is the 8th annual observance of National HIV/AIDS and Aging Awareness Day (NHAAAD), an opportunity to focus on the challenges facing the aging population regarding HIV prevention, testing, care, and treatment, as well as the health and well-being of the growing population of older people living with HIV.

alt

Read more:

High Standards of Care Associated with Reduced Mortality Risk for Veterans with HIV

Quality of care (QOC) during the first 12 months after entering HIV care is associated with longer-term mortality risk, investigators from the U.S. Department of Veterans Affairs report in the September 3 online edition of Clinical Infectious Diseases. Patients who received at least 80% of recommended quality of care indicators were 25% less likely to die during follow-up when compared to those who received less than 80%. Good outcomes were observed for people with drug or alcohol problems who received a high level of care.

alt

Read more:

Older People with HIV Have Reduced Life Expectancy

Mortality among HIV-positive people age 50 or older has fallen dramatically since the advent of effective combination antiretroviral therapy (ART) in the mid-1990s, but even well-treated people in this age group without AIDS-defining events or comorbidities have reduced survival time, on average, compared with the general population, according to a report in the August 27 advance edition of the Journal of Acquired Immune Deficiency Syndromes.

alt

Read more:

Vaginal Infections May Help Explain Link Between Hormonal Contraception and Increased HIV Risk

Hormones may alter genital tract immunity in a way that makes women more prone to bacterial and viral infections, while disturbances in natural vaginal microbes may also contribute to the association seen in some studies between use of hormonal contraceptives such as Dep-Provera and susceptibility to HIV infection, according to a laboratory study published in the online journal mBio.

alt

Read more:

U.S. Conference on AIDS Underway this Week in D.C.

The U.S. Conference on AIDS (USCA 2015), sponsored by the National Minority AIDS Council,is taking place this week, September 10-13, in Washington, D.C. The largest U.S. conference focused on the community-based response to HIV/AIDS, USCA brings together leaders of community organizations, care providers, public health workers, advocates, government policymakers, and people living with HIV.

alt

Read more:

New WHO Guidelines Recommend HIV Treatment for All and PrEP for Those at Risk

The World Health Organization (WHO) has released updated guidelines calling for universal antiretroviral therapy for everyone diagnosed with HIV, regardless of CD4 T-cell count, and pre-exposure prophylaxis (PrEP) for people at substantial risk of infection. The organization estimates that the recommendations, if widely adopted, could avert 21 million deaths and prevent 28 million new infections worldwide by 2030.

alt

Read more:

IAS 2015: Bone Loss Slows, but Continues Long-term in HIV-positive People on Antiretroviral Therapy

People with HIV experienced a decrease in bone density at the hip and spine during their first 2 years after starting antiretroviral therapy (ART). While bone loss slowed after 96 weeks, it continued to decline more rapidly among HIV-positive people compared with the usual age-related bone loss seen in HIV-negative people over 7 years, researchers reported at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.

alt

Read more:

September 27 Is National Gay Men's HIV/AIDS Awareness Day

September 27 is National Gay Men's HIV/AIDS Awareness Day (NGMHAAD), an annual opportunity to call attention to the disproportionate effect of the epidemic on gay and bisexual men. According to the CDC, gay, bisexual, and other men who have sex with men account for nearly two-thirds of new HIV infections in the U.S., despite making up approximately 2% of the population, with young black gay and bi men being most heavily affected.

alt

Read more:

IAS 2015: The TPP and Access to HIV and HCV Treatment [VIDEO]

The Trans-Pacific Partnership trade agreement, now under consideration, will heavily impact the availability of medications for HIV and viral hepatitis, both in middle-income countries and in high-income countries such as Canada that rely on generic drugs, advocates said at a Médecins Sans Frontières media briefing at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.

alt

Read more:

ICAAC 2015: New Antiretrovirals and HIV Treatment Strategies

Researchers presented findings from several HIV studies at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last week in San Diego, including an overview of the START treatment initiation study, an all-women antiretroviral therapy trial, and studies of a better tolerated version of tenofovir (tenofovir alafenamide or TAF) and the experimental integrase inhibitor cabotegravir.

alt

Read more:

Half of U.S. Gay Men Using Dating Apps Have Interacted with a PrEP User

Almost half of American gay men recruited to participate in a survey via advertising on a major mobile phone dating app say that at least one potential sexual partner has said that he was taking HIV pre-exposure prophylaxis (PrEP), and even more have interacted with someone who said that he was HIV-positive but had an undetectable viral load. Many of these potential partners were looking for sex without a condom, according to the survey results, published in the August 21 online edition ofJournal of Acquired Immune Deficiency Syndromes.

alt

Read more:

Awareness of Treatment Impact on HIV Transmission is Transforming Lives of Mixed-status Couples

A greater understanding of the impact of HIV treatment on prevention is changing the experience of being in a relationship with a partner of a different HIV status, according to a qualitative Australian study published recently in Sociology of Health and IllnessA biomedical intervention appears to be having unexpected effects -- loosening the association of serodiscordant relationships with "risk" and helping couples to experience their relationships as normal and safe.

alt

Read more:

IAS 2015: Peer-Led Intervention Lowers HIV Infections Among Drug Injectors in Ukraine

A cluster-randomized trial in Ukraine has shown that a peer education project reduced new HIV infections in people who inject drugs by 41%, researchers reported at the recent 8th Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.

alt

Read more:

ICAAC 2015: Combination Vaginal Ring May Be Able to Prevent Both HIV and Herpes

An experimental silicone vaginal ring with separate compartments may be able to deliver both tenofovir for prevention of HIV infection and acyclovir for prevention of genital herpes and potentially other sexually transmitted infections (STIs), according to a report at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last weekin San Diego.

alt

Read more:

IAS 2015: Rilpivirine + Darunavir HIV Maintenance Regimen Matches Standard 3-Drug ART

A NRTI-sparing dual antiretroviral regimen consisting of the NNRTI rilpivirine (Edurant) plus the boosted HIV protease inhibitor darunavir (Prezista) maintained viral suppression and was well-tolerated by people who switched from a standard 3-drug regimen, according to results from the PROBE study presented at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.

alt

Read more:

PROUD PrEP Study Results Published in The Lancet

The results of the PROUD study of HIV pre-exposure prophylaxis (PrEP) using daily tenofovir plus emtricitabine (Truvada) have now been published online in The Lancet scientific journal. PROUD, along with the other European randomized study of PrEP, Ipergay, demonstrated considerably higher levels of PrEP effectiveness in preventing HIV infections than any previous study. PrEP should now be offered routinely as part of sexual health services, says an accompanying editorial.

alt

Read more:

Needle Exchange May Have Prevented More Than 100 New HIV Infections in D.C.

A federal policy change allowing funding of syringe exchange programs in Washington, DC, averted 120 new HIV infections relative to the number that likely would have occurred had the funding ban remained in place, saving approximately $44 million, according to a mathematical modeling study published in the September 4 edition of AIDS and Behavior. "Our study adds to the evidence that needle exchange programs not only work but are cost-effective investments in the battle against HIV," said lead author Monica Ruiz.

alt

Read more:

U.S. PrEP Care Cascade Suggests Structural Barriers Must Be Addressed

The uptake of pre-exposure prophylaxis (PrEP) among people who need it risks being limited due to low levels of awareness, gaps in health insurance, opaque bureaucratic procedures, under-usage of medical services, and limited awareness and skills among healthcare providers, according to an analysis published online ahead of print in Clinical Infectious DiseasesAlso taking into account suboptimal adherence among some PrEP users, the researchers concluded that just 15% of gay men in Atlanta who could benefit are likely to achieve protection from HIV with PrEP.

alt

Read more:

IAS 2015: Many People with Long-term HIV Infection Do Not Achieve Full CD4 Cell Recovery

One-third of people who started combination antiretroviral therapy (ART) many years ago using first-generation protease inhibitors did not achieve complete immunological recovery with normal CD4 T-cell counts despite good viral suppression, according to a French study presented at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention in Vancouver.

alt

Read more: